KVD824

DRUG2 trials

Sponsors

KalVista Pharmaceuticals, Ltd.

Conditions

Angioedema, Hereditary, Types I and IIHereditary Angioedema

Phase 1

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

CompletedNCT05178355

KalVista Pharmaceuticals, Ltd.Hereditary Angioedema

Start: 2019-02-12End: 2019-06-21Updated: 2022-02-17

Phase 2

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

TerminatedNCT05055258

KalVista Pharmaceuticals, Ltd.Angioedema, Hereditary, Types I and II

Start: 2021-11-18End: 2022-10-27Updated: 2026-05-06